The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells
Open accessAbstract
Gaucher disease is caused by mutations in the glucocerebrosidase gene, which encodes the lysosomal hydrolase glucosylceramidase. Patients with Gaucher disease and heterozygous glucocerebrosidase mutation carriers are at increased risk of developing Parkinson's disease. Indeed, glucocerebrosidase mutations are the most frequent risk factor for Parkinson's disease in the general population. Therefore there is an urgent need to understand the mechanisms by which glucocerebrosidase mutations predispose to neurodegeneration to facilitate development of novel treatments. To study this we generated fibroblast lines from skin biopsies of five patients with Gaucher disease and six heterozygous glucocerebrosidase mutation carriers with and without Parkinson's disease. Glucosylceramidase protein and enzyme activity levels were assayed. Oxidative stress was assayed by single cell imaging of dihydroethidium. Glucosylceramidase enzyme activity was significantly reduced in fibroblasts from patients with Gaucher disease (median 5% of controls, P = 0.0001) and heterozygous mutation carriers with (median 59% of controls, P = 0.001) and without (56% of controls, P = 0.001) Parkinson's disease compared with controls. Glucosylceramidase protein levels, assessed by western blot, were significantly reduced in fibroblasts from Gaucher disease (median glucosylceramidase levels 42% of control, P < 0.001) and heterozygous mutation carriers with (median 59% of control, P < 0.001) and without (median 68% of control, P < 0.001) Parkinson's disease. Single cell imaging of dihydroethidium demonstrated increased production of cytosolic reactive oxygen species in fibroblasts from patients with Gaucher disease (dihydroethidium oxidation rate increased by a median of 62% compared to controls, P < 0.001) and heterozygous mutation carriers with (dihydroethidium oxidation rate increased by a median of 68% compared with controls, P < 0.001) and without (dihydroethidium oxidation rate increased by a median of 70% compared with controls, P < 0.001) Parkinson's disease. We hypothesized that treatment with the molecular chaperone ambroxol hydrochloride would improve these biochemical abnormalities. Treatment with ambroxol hydrochloride increased glucosylceramidase activity in fibroblasts from healthy controls, Gaucher disease and heterozygous glucocerebrosidase mutation carriers with and without Parkinson's disease. This was associated with a significant reduction in dihydroethidium oxidation rate of ∼50% (P < 0.05) in fibroblasts from controls, Gaucher disease and heterozygous mutation carriers with and without Parkinson's disease. In conclusion, glucocerebrosidase mutations are associated with reductions in glucosylceramidase activity and evidence of oxidative stress. Ambroxol treatment significantly increases glucosylceramidase activity and reduces markers of oxidative stress in cells bearing glucocerebrosidase mutations. We propose that ambroxol hydrochloride should be further investigated as a potential treatment for Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop
Settembre, C., De Cegli, R., Mansueto, G., Saha, P. K., Vetrini, F., Visvikis, O., Huynh, T., Carissimo, A., Palmer, D., Jürgen Klisch, T., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2718 · Cited by 1,022
Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways
Palmieri, M., Impey, S., Kang, H., di Ronza, A., Pelz, C., Sardiello, M., & Ballabio, A. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr306 · Cited by 1,022
Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
Hruska, K. S., LaMarca, M. E., Scott, C. R., & Sidransky, E. (2008) · Human Mutation · doi:10.1002/humu.20676 · Cited by 678
The link between the GBA gene and parkinsonism
Sidransky, E., & Lopez, G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70190-4 · Cited by 583
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains
Gegg, M. E., Burke, D., Heales, S. J. R., Cooper, J. M., Hardy, J., Wood, N. W., & Schapira, A. H. V. (2012) · Annals of Neurology · doi:10.1002/ana.23614 · Cited by 564
Self-citationChaperone-Mediated Autophagy Markers in Parkinson Disease Brains
Alvarez-Erviti, L., Rodriguez-Oroz, M. C., Cooper, J. M., Caballero, C., Ferrer, I., Obeso, J. A., & Schapira, A. H. V. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.198 · Cited by 554
Self-citationA Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies
Nalls, M. A., Duran, R., Lopez, G., Kurzawa-Akanbi, M., McKeith, I. G., Chinnery, P. F., Morris, C. M., Theuns, J., Crosiers, D., Cras, P., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1925 · Cited by 439
Lysosomal impairment in Parkinson's disease
Dehay, B., Martinez‐Vicente, M., Caldwell, G. A., Caldwell, K. A., Yue, Z., Cookson, M. R., Klein, C., Vila, M., & Bezard, E. (2013) · Movement Disorders · doi:10.1002/mds.25462 · Cited by 340
Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system
Lee, M. J., Lee, J. H., & Rubinsztein, D. C. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.03.001 · Cited by 336
Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease
Maegawa, G. H. B., Tropak, M. B., Buttner, J. D., Rigat, B. A., Fuller, M., Pandit, D., Tang, L., Kornhaber, G. J., Hamuro, Y., Clarke, J. T. R., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.012393 · Cited by 332
ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity
Ron, I., & Horowitz, M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi240 · Cited by 330
The genetics and neuropathology of Parkinson’s disease
Houlden, H., & Singleton, A. B. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1013-5 · Cited by 316
Protein degradation pathways in Parkinson’s disease: curse or blessing
Ebrahimi-Fakhari, D., Wahlster, L., & McLean, P. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1004-6 · Cited by 253
Wei, H., Kim, S.-J., Zhang, Z., Tsai, P.-C., Wisniewski, K. E., & Mukherjee, A. B. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddm324 · Cited by 209
Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders
Goker-Alpan, O., Stubblefield, B. K., Giasson, B. I., & Sidransky, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0741-7 · Cited by 181
The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease
Gan-Or, Z., Ozelius, L. J., Bar-Shira, A., Saunders-Pullman, R., Mirelman, A., Kornreich, R., Gana-Weisz, M., Raymond, D., Rozenkrantz, L., Deik, A., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31828f180e · Cited by 175
Rosenbloom, B., Balwani, M., Bronstein, J. M., Kolodny, E., Sathe, S., Gwosdow, A. R., Taylor, J. S., Cole, J. A., Zimran, A., & Weinreb, N. J. (2011) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2010.10.006 · Cited by 158
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology
Tsuang, D. W., Leverenz, J. B., López, O. L., Hamilton, R. L., Bennett, D. A., Schneider, J. A., Buchman, A. S., Larson, E. B., Crane, P. K., Kaye, J. A., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182735e9a · Cited by 156
Moran, M. T., Schofield, J. P., Hayman, A. R., Shi, G., Young, E. P., & Cox, T. M. (2000) · Blood · doi:10.1182/blood.v96.5.1969 · Cited by 153
Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond
Shachar, T., Bianco, C. L., Recchia, A., Wießner, C., Raas‐Rothschild, A., & Futerman, A. H. (2011) · Movement Disorders · doi:10.1002/mds.23774 · Cited by 153
Durán, R., Mencacci, N. E., Angeli, A., Shoai, M., Deas, E., Houlden, H., Mehta, A. B., Hughes, D. A., Cox, T. M., Deegan, P. B., et al. (2012) · Movement Disorders · doi:10.1002/mds.25248 · Cited by 147
Self-citationAmbroxol as a pharmacological chaperone for mutant glucocerebrosidase
Bendikov-Bar, I., Maor, G., Filocamo, M., et al. (2012) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2012.10.007 · Cited by 147
TFEB regulates lysosomal proteostasis
Song, W., Wang, F., Savini, M., Ake, A., di Ronza, A., Sardiello, M., & Segatori, L. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt052 · Cited by 143 · cited 2×
“The CLEAR network is regulated by transcription factor EB (TFEB), which acts to induce transcriptional upregulation of the CLEAR network in a synchronized fashion (Song et al., 2013).”
BackgroundPilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease.
Zimran, A., Altarescu, G., & Elstein, D. (2013) · Blood Cells, Molecules & Diseases · doi:10.1016/j.bcmd.2012.09.006 · Cited by 136
McNeill, A., Durán, R., Hughes, D. A., Mehta, A. B., & Schapira, A. H. V. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302402 · Cited by 111
Self-citationSawkar, A. R., Schmitz, M., Zimmer, K., Reczek, D., Edmunds, T., Balch, W. E., & Kelly, J. W. (2006) · ACS Chemical Biology · doi:10.1021/cb600187q · Cited by 102
Campeau, P. M., Rafei, M., Boivin, M., Sun, Y., Grabowski, G. A., & Galipeau, J. (2009) · Blood · doi:10.1182/blood-2009-02-205708 · Cited by 100
Tatti, M., Motta, M., Bartolomeo, S. D., Scarpa, S., Cianfanelli, V., Cecconi, F., & Salvioli, R. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds367 · Cited by 93
Vitner, E. B., Dekel, H., Zigdon, H., Shachar, T., Farfel‐Becker, T., Eilam, R., Karlsson, S., & Futerman, A. H. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq273 · Cited by 84
Clinical and genetic study of Japanese patients with type 3 Gaucher disease
Tajima, A., Yokoi, T., Ariga, M., Ito, T., Kaneshiro, E., Eto, Y., & Ida, H. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.05.001 · Cited by 83
Glucocerebrosidase Mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease
Kurzawa‐Akanbi, M., Hanson, P. S., Blain, P. G., Lett, D. J., McKeith, I. G., Chinnery, P. F., & Morris, C. M. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07879.x · Cited by 72
Otomo, A., Pan, L., & Hadano, S. (2012) · Neurology Research International · doi:10.1155/2012/498428 · Cited by 70
Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease
Schapira, A. H. V., & Gegg, M. E. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300822110 · Cited by 66
Self-citationBalwani, M., Fuerstman, L., Kornreich, R., Edelmann, L. J., & Desnick, R. J. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.302 · Cited by 65
Deganuto, M., Pittis, M. G., Pines, A., Dominissini, S., Kelley, M. R., Garcia, R. C., Quadrifoglio, F., Bembi, B., & Tell, G. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21023 · Cited by 54
Harries, L. W., Hattersley, A. T., & Ellard, S. (2004) · Diabetes · doi:10.2337/diabetes.53.2.500 · Cited by 53
In vitro and in vivo antioxidant activity of ambroxol
Štětinová, V., Herout, V., & Kvetina, J. (2004) · Clinical and Experimental Medicine · doi:10.1007/s10238-004-0050-3 · Cited by 52
Cell surface associated glycohydrolases in normal and Gaucher disease fibroblasts
Aureli, M., Bassi, R., Loberto, N., Regis, S., Prinetti, A., Chigorno, V., Aerts, J. M. F. G., Boot, R. G., Filocamo, M., & Sonnino, S. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9478-x · Cited by 44
Cited by
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Self-citationAutophagy: Regulator of cell death
Liu, S., Yao, S., Yang, H., Liu, S., & Wang, Y. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06154-8 · Cited by 1,125
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., Brassier, A., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020441 · Cited by 868
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
Self-citationMitochondrial dysfunction in Parkinson's disease
Bose, A., & Beal, M. F. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13731 · Cited by 841
Metadata
- Authors
- McNeill, A., Magalhaes, J., Shen, C., Chau, K.-Y., Hughes, D., Mehta, A., Foltynie, T., Cooper, J. M., Abramov, A. Y., Gegg, M., & Schapira, A. H. V.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-02-25
- Volume
- 137
- Issue
- 5
- Pages
- 1481-1495
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2134369114
- Cited by
- 321
- References
- 41
- FWCI
- 18.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.